Erythrocytosis on Testosterone Therapy: How High Is Too High
A single patient whose testosterone therapy is working exactly as intended, except for the hematocrit it has also driven up — and a deadline that makes the usual slow recheck cycle a genuine constraint rather than a formality.
Gary L., a 58-year-old commercial airline pilot, has felt genuinely better on testosterone cypionate injections for the past eighteen months — his libido, energy, and mood all improved, no complaints on the treatment itself. What his most recent routine labs caught is a hematocrit that has climbed from a pre-treatment baseline of 44 percent to 56 percent today, with no symptoms of hyperviscosity to announce it — no headache, no visual change, nothing that would have brought him in on its own. He is, however, due for his FAA medical certification exam in six weeks, and a hematocrit this elevated is exactly the kind of finding he’d rather address before an examiner sees it cold.
The two major guidelines on this exact scenario largely agree on where to act: the AUA recommends investigating once hematocrit exceeds 50 percent and reducing dose or holding therapy at 54 percent or above; the Endocrine Society sets its own action point at 54 percent, also endorsing dose reduction or, if needed, therapeutic phlebotomy. Gary is well past both thresholds. What the guidelines don’t settle as cleanly is mechanism-specific management: injectable testosterone produces the highest peak serum levels of any delivery route, and those peaks — not the drug’s average exposure — are what drive the strongest erythropoietin stimulation, which argues for addressing the peaks directly rather than simply lowering the total dose or reaching for the fastest available fix. Phlebotomy, the fix most likely to move his number before his exam, is also the one with the thinnest evidence behind it in this specific context — unlike its well-established role in polycythemia vera, its actual efficacy and safety for testosterone-induced erythrocytosis have not been established, and depleting iron stores carries its own theoretical thrombotic risk distinct from the elevated hematocrit itself.
In clinic, six weeks before his FAA exam
Switch him to a transdermal formulation. His injections are producing high peak levels every two weeks, and it's specifically the peak, not the average exposure, that drives the strongest erythropoietin stimulation. Changing the route addresses the actual mechanism rather than just chasing the number down.
I'd get most of that same peak-smoothing benefit by keeping him on injections but splitting the dose — smaller amounts, more often — without the cost and insurance-coverage disruption a formulation change can bring, especially six weeks before a deadline he cares about. Dose/frequency adjustment is also the more commonly practiced first step in both guidelines.
Either approach targets the same underlying peak-level problem — I don't think we're actually disagreeing about mechanism, just about which route gets there with less disruption to him right now.
Before either of you gets to phlebotomy as a backup plan, I want to name something directly: the evidence for phlebotomy actually helping in testosterone-induced erythrocytosis is thin. It's well established for polycythemia vera, a different disease with a different physiology, but here it hasn't been shown to be safe or effective, and depleting iron stores can itself raise thrombotic risk through a separate pathway from the hematocrit we're trying to lower.
I understand the deadline pressure, but 'we don't have time to wait for a dose change to work' isn't a reason to reach for an option whose own safety in this exact situation hasn't been established either.
Agreed: switch to twice-weekly lower-dose subcutaneous testosterone, evening out peak levels relative to his prior less-frequent injection schedule, with hematocrit rechecked in three weeks — an incomplete washout period, but enough to have real data in hand before his FAA exam. Therapeutic phlebotomy held in reserve only if that recheck remains concerning and truly urgent.
Not agreed: whether Gary should proactively disclose today’s hematocrit to his aviation medical examiner before the recheck rather than waiting to see the new number first. The urologist believes proactive disclosure is right regardless of outcome; the endocrinologist feels that decision belongs to Gary and his examiner, not something the treating physicians should push one way or the other.